BioXcel Therapeutics (BTAI) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTAI shares.
View BTAI analyst ratings or view top-rated stocks.

7 analysts have issued 1 year target prices for BioXcel Therapeutics' stock. Their BTAI share price forecasts range from $22.00 to $76.00. On average, they anticipate the company's stock price to reach $50.29 in the next twelve months. This suggests a possible upside of 166.5% from the stock's current price.
View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts.

BioXcel Therapeutics' stock was trading at $21.48 at the start of the year. Since then, BTAI shares have decreased by 12.2% and is now trading at $18.87.
View the best growth stocks for 2023 here.

BioXcel Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 3,350,000 shares, a decline of 5.4% from the April 30th total of 3,540,000 shares. Based on an average trading volume of 518,100 shares, the short-interest ratio is presently 6.5 days. Approximately 16.7% of the shares of the company are sold short.
View BioXcel Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our BTAI earnings forecast.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its earnings results on Monday, May, 8th. The company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.56) by $0.28. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.50 million. During the same period last year, the firm posted ($1.12) earnings per share.

ETFs with the largest weight of BioXcel Therapeutics (NASDAQ:BTAI) stock in their portfolio include WisdomTree Artificial Intelligence and Innovation Fund (WTAI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

(BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

BioXcel Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (14.74%), State Street Corp (6.04%), BlackRock Inc. (4.72%), Wellington Management Group LLP (4.60%), Artemis Investment Management LLP (3.38%) and Geode Capital Management LLC (1.31%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart, Vimal Mehta and Vincent O'neill.
View institutional ownership trends.

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BTAI stock can currently be purchased for approximately $18.87.

BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $550.25 million and generates $380,000.00 in revenue each year. The company earns $-165,760,000.00 in net income (profit) each year or ($6.63) on an earnings per share basis.

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com.